Navigation Links
Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
Date:11/11/2009

linical development of BGLP40 in 2011, our decision to move PX-866 into Phase 2 clinical development in the first half of 2010 and our expectations regarding completion of patient enrollment in our Phase 1 trial of PX-478 in the fourth quarter of 2009;and the use and adequacy of cash resources.

Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including the risks associated with the costs and expenses of developing our product candidates, the adequacy of financing and cash reserves on hand, changes in general accounting policies, general economic factors, achievement of the results we anticipate from our clinical trials with our products and pre-clinical development of our product candidates and our ability to adequately obtain and protect our intellectual property rights. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Additional Information

Additional information relating to Oncothyreon can be found on U.S. EDGAR at www.sec.gov and on SEDAR at www.sedar.com.

                               Oncothyreon Inc.

    Consolidated Statements of Operations a
'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Oncothyreon announces webcast of third quarter 2009 financial results conference call
2. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
3. Oncothyreon to present at Rodman Renshaw Global Healthcare Conference
4. Oncothyreon reports second quarter 2009 financial results
5. Oncothyreon announces closing of $15.0 million registered direct financing
6. Oncothyreon announces webcast of second quarter 2009 financial results conference call
7. Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
8. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
9. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
10. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
11. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015  PDS Biotechnology ... cancer immunotherapy treatment targeting HPV-16, has generated strong ... Currently, pre-cervical cancer is treated by surgical ... simple and effective non-surgical alternative. Results show that ... (T-cells) to recognize, target, and kill precancerous and ...
(Date:5/28/2015)... The Fertility Centers of New England is proud to ... on a new and expanded role as Medical Director. ... oversight and quality assurance for the practice. , “We ... of experienced reproductive endocrinologists,” said Fertility Centers of New ... expertise and compassionate, individualized care have helped set FCNE ...
(Date:5/28/2015)... Rochelle, Virginia (PRWEB) May 28, 2015 ... Partners LLC announced today that Roger L. Williams, ... Expert consultant. NDA Partners Premier Experts are top ... them to bring extraordinary value to the company’s ... critical solutions to help clients successfully develop their ...
(Date:5/27/2015)... 26, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "Molecular ... to their offering. This report ... that will play an important role in ... forensics and biological warfare in the 21st ...
Breaking Biology Technology:PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2Former CEO and Chair of the Council of Experts at the USP, Roger L. Williams, MD, Joins NDA Partners as a Premier Expert Consultant 2Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 2Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 3
... Osaka, Japan, for the Bio Japan 2006 conference as ... of times over the years about both the Japanese pharma and ... few years and I'm looking forward to getting up to speed ... reminder: Chicago and Osaka are sister cities and my last visit ...
... EraGen Biosciences , a Madison-based developer of diagnostic ... outline its product development plans. , ,Irene Hrusovsky, CEO ... of the company to attendees of the Mid-America ... of ZyStor Therapeutics, Inc. , a Milwaukee-based developer ...
... other TV news broadcasts, the accusation that Hewlett ... of directors was revealed. Because she was afraid that ... Patricia Dunn, unilaterally authorized a project headed up by ... personal phone records of board members. www.msnbc.msn.com/id/14687677/site/newsweek ...
Cached Biology Technology:Chinese pharma-biotech dragon rears its head 2Chinese pharma-biotech dragon rears its head 3Chinese pharma-biotech dragon rears its head 4Chinese pharma-biotech dragon rears its head 5Chinese pharma-biotech dragon rears its head 6EraGen set to highlight diagnostic products at BIO 2Compliance at HP - Pretexting paranoia 2Compliance at HP - Pretexting paranoia 3Compliance at HP - Pretexting paranoia 4Compliance at HP - Pretexting paranoia 5
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... Yamanaka MD, PhD, of Kyoto University and the Gladstone ... forward in improving the possibilities for the practical application ... Dr. Yamanaka had shown that adult cells can be ... oncogene as one of the four genes required to ...
... Jim Doyle today announced a historic collaboration between ... care leading to health care that proactively addresses ... research effort among the Marshfield Clinic, Medical College ... Medicine and Public Health (UWSMPH) and UW-Milwaukee (UWM). ...
... one of the most thoroughly studied organisms in the ... understanding variation in physiology, behavior, life history and morphology ... On biological levels from molecular and genetic to developmental ... it has proven far more complex than even imagined. ...
Cached Biology News:Yamanaka eliminates viral vector in stem cell reprogramming 2Governor Doyle announces historic genomic research collaboration 2Fitness in a changing world 2Fitness in a changing world 3
The Bio-Plex Manager version 3.0 to 4.0 workstation software upgrade kit is used to upgrade existing Bio-Plex Manager version 3.0 software to version 4.0 security edition software....
... --- a cocktail of 3 siRNAs specifically ... our most popular product. The siTrio reagent ... of your target gene when used under ... and confirmation of optimal transfection with one ...
... Spring offers a large collection of ... fetal tissuea, cell lines, and mouse ... in pHD9 vector. The size of ... be from 200bp to 1000bp by ...
... #27295 has improved stability and convenience from the ... only has overcome this problem but also produced ... changed the formulation of HRP conjugated antibody from ... this change, the stability of the conjugate has ...
Biology Products: